Qualigen Therapeutics (NASDAQ:QLGN) Announces Quarterly Earnings Results

Qualigen Therapeutics (NASDAQ:QLGNGet Rating) issued its earnings results on Friday. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.05, MarketWatch Earnings reports.

Shares of NASDAQ:QLGN opened at $0.53 on Friday. The firm has a 50 day moving average of $0.62 and a 200-day moving average of $0.89. Qualigen Therapeutics has a 12 month low of $0.45 and a 12 month high of $3.12.

Several large investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of Qualigen Therapeutics in the 1st quarter valued at approximately $75,000. JPMorgan Chase & Co. raised its position in shares of Qualigen Therapeutics by 4,992,900.0% in the 4th quarter. JPMorgan Chase & Co. now owns 99,860 shares of the company’s stock valued at $107,000 after buying an additional 99,858 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Qualigen Therapeutics by 31.1% in the 3rd quarter. Geode Capital Management LLC now owns 221,146 shares of the company’s stock valued at $287,000 after buying an additional 52,444 shares in the last quarter. Institutional investors own 7.57% of the company’s stock.

About Qualigen Therapeutics (Get Rating)

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood.

Featured Articles

Earnings History for Qualigen Therapeutics (NASDAQ:QLGN)

Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.